Premium
BCL2L1 has a functional role in colorectal cancer and its protein expression is associated with chromosome 20q gain
Author(s) -
SillarsHardebol Anke H,
Carvalho Beatriz,
Beliën Jeroen AM,
de Wit Meike,
Delisvan Diemen Pien M,
Tijssen Marianne,
van de Wiel Mark A,
Pontén Fredrik,
Fijneman Remond JA,
Meijer Gerrit A
Publication year - 2012
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.2983
Subject(s) - colorectal cancer , biology , messenger rna , cancer research , cancer , gene , genetics
Abstract Colorectal cancer (CRC) is the second leading cause of cancer death in the western world. The majority of CRCs, which develop from adenoma precursor lesions, show gain of chromosome arm 20q, where BCL2L1 is located. BCL2L1 is an important apoptosis regulating gene that codes for both an anti‐apoptotic ( Bcl‐x L ) and a pro‐apoptotic ( Bcl‐x S ) splice variant. The aim of the present study was to investigate whether BCL2L1 contributes to 20q gain‐driven colorectal adenoma‐to‐carcinoma progression. To this end, the functional role of BCL2L1 in cancer‐related processes was investigated, and differences in BCL2L1 DNA, mRNA, and protein levels were compared between colorectal adenomas and CRCs, as well as between tumours with and without 20q gain. Down‐modulation of BCL2L1 inhibited cell viability and anchorage‐independent growth of CRC cells, while invasion was not affected. BCL2L1 DNA copy number and protein expression were increased in CRCs compared to adenomas ( p = 0.00005 and p = 0.03, respectively), while mRNA expression was not. Differences in BCL2L1 protein expression were even more pronounced between tumours with and without 20q gain ( p = 0.0001). In conclusion, BCL2L1 is functionally involved in several cancer‐related processes and its protein expression is associated with 20q gain. This supports a role for 20q gain‐dependent expression of BCL2L1 in colorectal adenoma‐to‐carcinoma progression. However, the absence of a direct correlation between BCL2L1 mRNA and protein expression implies that BCL2L1 protein expression is regulated at the post‐transcriptional level by a distinct factor on the 20q amplicon (eg ZNF217, AURKA or miRNAs). Therefore, even though BCL2L1 affects CRC biology in a 20q gain‐dependent manner, it is not likely to be a driver of chromosome 20q gain associated adenoma‐to‐carcinoma progression. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.